Therapeutic Strategies in Lymphoid Malignancies: An Immunotherapeutic Approach
Clinical Publishing, August 2005, Pages: 248
Targeted therapies are the focus of much research in oncology. Encouraging results from the development of new monoclonal antibodies are revolutionizing clinical therapies and this is particularly the case for haematologic malignancies. The advent of immunotherapy heralds a new era particularly for patients who are refractory to more traditional therapies. Impressive results are evident using monoclonal antibodies (mAb) that a) bind with high specificity to cell-surface antigens, resulting in targeted killing of the malignant cells or b) are conjugated to radioisotopes, toxins, enzymes or drugs that have the potential to reach high concentration at the tumour site. Not only do these agents improve remission and overall survival, but also many new studies have shown that they can be even more effective when used in combination with more traditional therapies. This unique book brings together a series of topical discussions of how the new immunotherapeutic agents can be used successfully to treat lymphoid malignancies. The contributors are prestigious clinicians and researchers working at the cutting edge of the field. This will be an invaluable resource for the haematologist or oncologist who will find up-to-date data and clinical advice regarding the latest immunotherapeutic options in haematology.
Benefits:
- Concise and up to date review of the latest clinical developments
- International team of contributors drawing on numerous centres of excellence
- Enables the reader to choose appropriate therapeutic options for individual patients
Readership:
- Clinical oncologists and haematologists
- Clinical researchers
Contributors
1. The history of immunotherapy for lymphoid malignancies
Håkan Mellstedt
2. Immunologic markers of lymphoid malignancy
Andrew S. Jack
3. Diagnostic and prognostic markers of lymphoid malignancies; the latest genetic, cytogenic and haematological parameters
Terry J. Hamblin
4. CD20: B-cell antigen and therapeutic target
Peter McLaughlin, Julie P. Deans
5. Rituximab and chemotherapy for non-Hodgkin’s lymphomas: improved response and survival
Francisco J. Hernandez-Ilizaliturri, Myron Stefan Czuczman
6. Rituximab and chemotherapy in elderly patients with lymphomas
Bertrand Coiffier
7. Maintenance therapy with rituximab
Bruce D. Cheson, Blanche H. Mavromatis
8. Interferon-alpha in lymphoid malignancies
Jean-Luc Harousseau, Viviane Dubruille
9. Radioimmunotherapy safety: radiation protection, administration guidelines, isotope comparison, and quality of life issues
Brett Thomas Brinker, Leo I. Gordon
10. Radioimmunotherapy with Yttrium-90-labelled ibritumomab tiuxetan (Zevalin™) for B-cell non-Hodgkin’s lymphoma
Thomas E. Witzig
11. Radioimmunotherapy combinations with other therapies for non-Hodgkin’s lymphoma
Christos Emmanouilides
12. 131I-Tositumomab therapy for the treatment of low-grade non-Hodgkin’s lymphoma
Andrzej J. Jakubowiak, Mark S. Kaminski
13. CD52 as a target for immunotherapy
Martin J. S. Dyer
14. Relapsed and refractory CLL: a clinical challenge
Kanti R. Rai, N. Driscoll, D. M. Janson, D. V. Patel
15. Optimising the use of alemtuzumab in CLL: new therapeutic end-points, disease stratification and therapy earlier in the disease course
Peter Hillmen
16. Alemtuzumab in combination with other therapies in B-cell lymphoproliferative disorders
Karen W. L. Yee, Susan M. O’Brien
17. The role of alemtuzumab in allogeneic stem cell transplantation
Karl S. Peggs
18. Alemtuzumab in T-cell malignancies
Farhad Ravandi, Michael Keating
19. Epratuzumab: A new humanised monoclonal antibody to CD22
Morton Coleman, Richard R. Furman, Julian Decter, William A. Wegener,
Ivan D. Horak, David M. Goldenberg, John P. Leonard
20. Education and management of patients undergoing immunotherapy and radioimmunotherapy
Nancy L. Tuinstra
21. Antibody therapy for chronic lymphocytic leukaemia
John C. Byrd, Kristie A. Blum, Thomas S. Lin
Index
Edited by:
- P Hillmen, Haematology Malignancy Diagnostic Service, Leeds General Infirmary, Leeds, UK
- TE Witzig, Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
